News Image

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Provided By GlobeNewswire

Last update: Sep 25, 2024

LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a local drug-delivery platform, today announced that it is increasing the production of its FDA-cleared RenovoCath catheter-based delivery system due to increased demand for targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.

Read more at globenewswire.com

RENOVORX INC

NASDAQ:RNXT (8/22/2025, 8:00:02 PM)

After market: 0.93 -0.01 (-1.1%)

0.9403

+0.05 (+5.25%)



Find more stocks in the Stock Screener

RNXT Latest News and Analysis

8 days ago - By: Chartmill - Mentions: FOSL INO XNET TPIC ...
Follow ChartMill for more